Cargando…
Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538193/ https://www.ncbi.nlm.nih.gov/pubmed/37766075 http://dx.doi.org/10.3390/vaccines11091397 |
_version_ | 1785113270515924992 |
---|---|
author | Mahmoud, Sara H. Khalil, Ahmed A. Abo Shama, Noura M. El Sayed, Marwa F. Soliman, Reem A. Hagag, Naglaa M. Yehia, Nahed Naguib, Mahmoud M. Arafa, Abdel-Sattar Ali, Mohamed A. El-Safty, Mounir M. Mostafa, Ahmed |
author_facet | Mahmoud, Sara H. Khalil, Ahmed A. Abo Shama, Noura M. El Sayed, Marwa F. Soliman, Reem A. Hagag, Naglaa M. Yehia, Nahed Naguib, Mahmoud M. Arafa, Abdel-Sattar Ali, Mohamed A. El-Safty, Mounir M. Mostafa, Ahmed |
author_sort | Mahmoud, Sara H. |
collection | PubMed |
description | Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1.2, H5N8 clade 2.3.4.4b and the recent H5N1 clade 2.3.4.4b, have been reported among poultry populations in Egypt. This demanded the utilization of a nationwide routine vaccination program in the poultry sector. Antigenic differences between available avian influenza vaccines and the currently circulating H5Nx strains were reported, calling for an updated vaccine for homogenous strains. In this study, three H5Nx vaccines were generated by utilizing the reverse genetic system: rgH5N1_2.3.4.4, rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. Further, the immunogenicity and the cross-reactivity of the generated inactivated vaccines were assessed in the chicken model against a panel of homologous and heterologous H5Nx HPAIVs. Interestingly, the rgH5N1_2.3.4.4 induced high immunogenicity in specific-pathogen-free (SPF) chicken and could efficiently protect immunized chickens against challenge infection with HPAIV H5N1_2.3.4.4, H5N8_2.3.4.4 and H5N1_2.2.1.2. In parallel, the rgH5N1_2.2.1.2 could partially protect SPF chickens against infection with HPAIV H5N1_2.3.4.4 and H5N8_2.3.4.4. Conversely, the raised antibodies to rgH5N1_2.3.4.4 could provide full protection against HPAIV H5N1_2.3.4.4 and HPAIV H5N8_2.3.4.4, and partial protection (60%) against HPAIV H5N1_2.2.1.2. Compared to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2 vaccines, chickens vaccinated with rgH5N1_2.3.4.4 showed lower viral shedding following challenge infection with the predefined HPAIVs. These data emphasize the superior immunogenicity and cross-protective efficacy of the rgH5N1_2.3.4.4 in comparison to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. |
format | Online Article Text |
id | pubmed-10538193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105381932023-09-29 Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses Mahmoud, Sara H. Khalil, Ahmed A. Abo Shama, Noura M. El Sayed, Marwa F. Soliman, Reem A. Hagag, Naglaa M. Yehia, Nahed Naguib, Mahmoud M. Arafa, Abdel-Sattar Ali, Mohamed A. El-Safty, Mounir M. Mostafa, Ahmed Vaccines (Basel) Article Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1.2, H5N8 clade 2.3.4.4b and the recent H5N1 clade 2.3.4.4b, have been reported among poultry populations in Egypt. This demanded the utilization of a nationwide routine vaccination program in the poultry sector. Antigenic differences between available avian influenza vaccines and the currently circulating H5Nx strains were reported, calling for an updated vaccine for homogenous strains. In this study, three H5Nx vaccines were generated by utilizing the reverse genetic system: rgH5N1_2.3.4.4, rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. Further, the immunogenicity and the cross-reactivity of the generated inactivated vaccines were assessed in the chicken model against a panel of homologous and heterologous H5Nx HPAIVs. Interestingly, the rgH5N1_2.3.4.4 induced high immunogenicity in specific-pathogen-free (SPF) chicken and could efficiently protect immunized chickens against challenge infection with HPAIV H5N1_2.3.4.4, H5N8_2.3.4.4 and H5N1_2.2.1.2. In parallel, the rgH5N1_2.2.1.2 could partially protect SPF chickens against infection with HPAIV H5N1_2.3.4.4 and H5N8_2.3.4.4. Conversely, the raised antibodies to rgH5N1_2.3.4.4 could provide full protection against HPAIV H5N1_2.3.4.4 and HPAIV H5N8_2.3.4.4, and partial protection (60%) against HPAIV H5N1_2.2.1.2. Compared to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2 vaccines, chickens vaccinated with rgH5N1_2.3.4.4 showed lower viral shedding following challenge infection with the predefined HPAIVs. These data emphasize the superior immunogenicity and cross-protective efficacy of the rgH5N1_2.3.4.4 in comparison to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. MDPI 2023-08-22 /pmc/articles/PMC10538193/ /pubmed/37766075 http://dx.doi.org/10.3390/vaccines11091397 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mahmoud, Sara H. Khalil, Ahmed A. Abo Shama, Noura M. El Sayed, Marwa F. Soliman, Reem A. Hagag, Naglaa M. Yehia, Nahed Naguib, Mahmoud M. Arafa, Abdel-Sattar Ali, Mohamed A. El-Safty, Mounir M. Mostafa, Ahmed Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses |
title | Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses |
title_full | Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses |
title_fullStr | Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses |
title_full_unstemmed | Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses |
title_short | Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses |
title_sort | immunogenicity and cross-protective efficacy induced by an inactivated recombinant avian influenza a/h5n1 (clade 2.3.4.4b) vaccine against co-circulating influenza a/h5nx viruses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538193/ https://www.ncbi.nlm.nih.gov/pubmed/37766075 http://dx.doi.org/10.3390/vaccines11091397 |
work_keys_str_mv | AT mahmoudsarah immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT khalilahmeda immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT aboshamanouram immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT elsayedmarwaf immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT solimanreema immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT hagagnaglaam immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT yehianahed immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT naguibmahmoudm immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT arafaabdelsattar immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT alimohameda immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT elsaftymounirm immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses AT mostafaahmed immunogenicityandcrossprotectiveefficacyinducedbyaninactivatedrecombinantavianinfluenzaah5n1clade2344bvaccineagainstcocirculatinginfluenzaah5nxviruses |